Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKYO vs SPRC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKYO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

OKYO Overall Winner 6-Pillar Tally: OKYO 3 – 2 SPRC (1 Tie) Matrix Metrics: OKYO 5 – 2 SPRC

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) is the stronger overall head-to-head candidate over SciSparc Ltd. (SPRC) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas SPRC carries 44.2/100 (HOLD) at $0.20 (N/M Forward P/E, -725.2% operating margin).

  • Composite vs. Pillar Nuance: While SPRC currently prints a higher short-term Unified Composite Score (44.2/100 HOLD vs. OKYO 42.8/100 HOLD), OKYO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -725.2% operating margin) and revenue trajectory (+0.0% vs. -38.4% YoY).
  • Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile SPRC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 14.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKYO vs SPRC
OKYO NASDAQ Head-to-Head Winner
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38
SPRC NASDAQ
SciSparc Ltd. Ordinary Shares
Retail-Auto Dealers & Gasoline Stations
$0.20
-34.83% 1D
Market Cap $739,034
TTM Revenue $679,000
Forward P/E N/M
Beta / 30D Vol 0.93β · 205% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -47.0%), weak momentum, RSI 14
RSI-14: 14.5 · SMA20: $0.51 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (OKYO 3 – 2 SPRC)

Columns: Metric · OKYO · SPRC
1. Valuation Multiples SPRC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale OKYO
Revenue Growth (YoY) +0.0% -38.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $679,000
Market Cap $62.7M $739,034
3. Profitability & Quality OKYO
Gross Margin N/A N/A
Operating Margin 0.0% -725.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -263.8% -164.5%
4. Balance Sheet & Cash Flow SPRC
Cash Generation (TTM) N/A -$4.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.23 Book/Sh · -263.8% ROE $6.79 Book/Sh · -164.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OKYO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKYO (5) vs SPRC (2)
Institutional Metric OKYO SPRC Criterion Row Edge
Market Capitalization
Scale
$62.7M $739,034 Larger Scale OKYO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -38.4% Higher Growth OKYO
Operating Margin (TTM)
Profitability
0.0% -725.2% Higher Margin OKYO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-263.8% -164.5% Higher ROE SPRC
52-Week Range Position
Momentum
3% ($1–$3) 0% ($0–$16) Stronger Trend OKYO
Beta / 30D Volatility
Risk Regime
1.05β · 76% Vol 0.93β · 205% Vol Lower Realized Risk OKYO
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite SPRC
Trailing 12M Revenue (USD)
Operating Scale
N/A $679,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.23 Book/Sh · -263.8% ROE) -$4.8M EBITDA ($6.79 Book/Sh · -164.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKYO +56.5 pp
OKYO: -27.21% · SPRC: -83.71%
3M Horizon OKYO +68.39 pp
OKYO: -28.67% · SPRC: -97.06%
6M Horizon OKYO +61.06 pp
OKYO: -34.36% · SPRC: -95.42%
1Y Horizon OKYO +45.02 pp
OKYO: -47.03% · SPRC: -92.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs SPRC. Trailing 12-month operating profitability (OKYO 0.0% vs SPRC -725.2%) and valuation multiples (OKYO N/M vs SPRC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M
SPRC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$679,000
Gross MarginN/A
Op. Margin-725.2%
ROE / Fwd P/E-164.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SPRC BREAKDOWN
117d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact SPRC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SPRC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $739,034 market capitalization and -725.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OKYO vs SPRC Key Questions & Quantitative Answers

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) is the stronger overall head-to-head candidate over SciSparc Ltd. (SPRC) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas SPRC carries 44.2/100 (HOLD) at $0.20 (N/M Forward P/E, -725.2% operating margin). Composite vs. Pillar Nuance: While SPRC currently prints a higher short-term Unified Composite Score (44.2/100 HOLD vs. OKYO 42.8/100 HOLD), OKYO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -725.2% operating margin) and revenue trajectory (+0.0% vs. -38.4% YoY). Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile SPRC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 14.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OKYO leads the Growth & Scale pillar: OKYO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SPRC at -38.4% YoY revenue growth and +0.0% YoY earnings growth on $679,000 TTM revenue (N/A gross margin, -725.2% operating margin). On trailing 12-month operating scale, OKYO generates N/A in USD-normalized revenue versus $679,000 for SPRC. In operating R&D and SG&A reinvestment, OKYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SPRC.

SPRC screens cheaper on headline valuation multiples. OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SPRC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKYO (-263.8% ROE) versus SPRC (-164.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, SPRC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.93β · 205% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.